Acquired a New Asset? Look Out for These 3 CMC Data Challenges

Life science M&A is revving back up. For CMC programs, that’s the good news…

With most of 2024 in the books, we can officially call it: M&A activity is finally bouncing back for pharma and biotech.

True, today’s deals look a little different from the mega-buyouts of the past, with a lot less M and a good bit more A (think: fewer monster mergers and rollups and more small(er) strategic acquisitions that fill specific pipeline gaps and help offset the impact of looming patent cliffs). But still, it’s welcome news for anyone who has spent the last few years buckling down and weathering a serious rough patch in drug development’s capital market. 

Freshly juiced pipelines, attractive licensing opportunities, and a few more big exits, anyone? Yes, please… right?

It might depend on who you ask. No doubt the front office and top floor will be excited about the new momentum. But while those promising new drugs or compounds may be a welcome pipeline boost, new acquisitions often arrive with something else that’s not an exciting molecule: a lot of data integrity and knowledge management baggage.

Let’s look at what that can mean for the new owner’s CMC program.

For CMC leaders, dry ink can bring some high stakes.

Whether it’s uniting two organizations or “just” an asset acquisition, M&A is a massive, complex undertaking in the life sciences. It’s a process with thousands of layers—financial, legal, organizational, cultural, and more—all of which need to be rigorously planned and painstakingly executed, with millions if not billions of dollars of dollars riding on a successful deal. 

And as with any process that complex and capital-intensive, the price of failure can be eye-wateringly high. Just ask the folks who bought Actelion, scrapped a Phase 3 program purchased for $4.7 billion, or sprang for ownership of “female Viagra.” Those are but a few of the many cautionary tales with costs paid in 9-figure writedowns, abandoned late-stage trials, and early exits from the C-Suite

But of course, with so much on the line and so many stakeholders to appease—or at least not seriously disappoint—the CMC data for an acquisition target must be de-risked down to the last metadata label, right? Of course those encyclopedic due diligence checklists cover every stability dataset and clinical batch record?

Dial “483” for a reality check, my friends. Here are just a few of the challenges CMC programs face when newly acquired data arrives on their shores.

M&A is a massive, complex undertaking in the life sciences. It’s a process with thousands of layers—financial, legal, organizational, cultural, and more—all of which need to be rigorously planned and painstakingly executed, with millions if not billions of dollars of dollars riding on a successful deal.

Challenge 1: How acquired CMC data arrives

When the press releases start flying, CMC leaders’ work is often just beginning. At that point, they’ve just been handed the task of harmonizing an entire third-party CMC program with their own. And since CMC data resources aren’t exactly known for being developed or maintained in the most purposeful, structured fashion, that’s typically no small undertaking.

In fact, when IP changes hands, one of the first things to flood a CMC program is data: lots of it, mostly unstructured, and usually trapped in voluminous PDFs, spreadsheets, and Word Documents. Frequently, it comes in the simple but ominous form of a SharePoint login.

You don’t need to be a dungeon master to know how long of a journey lies beyond those gates.

Spend just a few minutes in a typical trove of CMC data, and you’ll quickly see why the average tech transfer takes so long, and why regulators are forcefully pushing for structured submissions. Sifting your own organization’s mountain of data is a time-consuming task; at least you likely know where to start. But somebody else’s? I’ve never tried finding my way out of the Paris catacombs with a map written in Tagalog, but I imagine it would be a similar experience. 

The process of simply figuring out what’s there can be a daunting experience for CMC programs receiving newly acquired product and process information. Especially when—trigger warning—it comes in the form of hundreds of inscrutably named PDFs or years of experiment data accumulated in a single multi-hundred-tab XLS. 

In the best-case scenario, of course, all that knowledge will at least be consolidated in one place, behind one login. But even if it is, another big question remains to be answered: How was that knowledge managed and structured?

Challenge 2: Different knowledge management frameworks… if any at all

Even if all an acquisition’s CMC data is in one place—and that’s a substantial if—that can still be just the beginning of the onboarding odyssey. Data, after all, is just the raw material. Its real value starts with how it’s managed and structured. 

But that, of course, brings us to yet another big if. 

Different organizations may apply completely different labeling strategies to their data, establishing vastly different taxonomies for the information they accumulate in documents. They may have different SOPs for how data should be documented. In CMC’s (in)famously heterogeneous ecosystem, even the simplest variables and most fundamental attributes can often go by many different, mutually unintelligible names from one document to the next. 

In a perfect world, of course, every drug developer with an eye toward M&A would be using a robust knowledge management system (they sell them off the shelf these days!) and using FAIR principles to organize and structure their data resources. Just these two powerful resources can help CMC programs ensure rigorous integrity and out-of-the-box utility across their knowledge base—and it’s exciting to see just how many drug developers have already realized that

But while Digital CMC best practices may be taking root more widely than ever, the industry still has a ways to go in transforming how it manages CMC knowledge. Until it gets there, many translation and harmonization challenges will still await programs once they gather all their new acquisition’s information.

Even if all an acquisition’s CMC data is in one place—and that’s a substantial if—that can still be just the beginning of the onboarding odyssey. Data, after all, is just the raw material. Its real value starts with how it’s managed and structured. But that, of course, is yet another big if.

Challenge 3: Brain-sized gaps in tribal knowledge

Curation issues, of course, assume that a product’s data has at least been collected somewhere it can be accessed—even if that’s in a document. But what’s an acquirer to do when even that hasn’t happened? 

At far too many CMC programs, critical knowledge—process variables, risk factors, historical outcomes, experiment results, and more—may not even reach SharePoint. Instead, it’s “stored” in the minds of CMC contributors handling day-to-day tasks off a mental cache no one else on their team can access, much less the organization that purchases that implicit knowledge. 

And if that weren’t enough of a risk to a successful acquisition, few industry events spell turnover like “M&A.” When products change hands or organizations unite, those transitions often bring staffing shakeups, headcount changes, and redundancies too. Every departing teammate is one who can walk out the door with critical information in their head, never to be received by the organization that paid up for what they know. 

It can be a painful moment when that acquirer realizes that part of their investment is polishing their LinkedIn profile instead of the new owner’s pipeline valuation. But it’s a common scenario when CMC programs don’t plan ahead to secure the knowledge  they plan to sell with their product. 

So what’s a smart CMC program to do?

Luckily, none of these challenges are inevitable. Today’s CMC leaders have many ready-to-hand resources that can help them mitigate or even eliminate some of the most serious issues they may face when onboarding a new asset—from purpose-built knowledge management platforms to a growing community of Digital CMC experts who’ve been there and done that.

Even following just a few best practices and proven data management principles can put a program miles ahead in preparing to support a successful acquisition. Having an established knowledge management framework provides a structured destination for all incoming information. FAIR principles provide a unifying strategy for curating inbound data so it can become part of your institutional knowledge, no matter how it was previously managed (or if it was). 

Of course, having a proven playbook matters too. And that’s one way today’s M&A’ers are at a huge advantage: there’s a growing range of proven use cases and established best practices for managing CMC knowledge, integrating CMC workflows, and seamlessly moving product and process data through that ecosystem.

Just in time for a big surge of dealmaking activity!

Let us help streamline your new asset integration process

Here at QbDVision, we’ve helped guide numerous organizations through the complexities of onboarding a new asset. And we’d love to do the same for you. 

Get in touch to learn more about how QbDVision can help you implement a structured data framework for all your existing CMC knowledge—and lay the groundwork for successful integration of new acquisitions. 

GET IN TOUCH

Getting ready to onboard a new asset?

Reach out to our team at any time to learn more about how QbDVision can help you streamline integration and accelerate the value of your new acquisition.

Tim Adkins

Director of Digital Life Sciences Operations, ZÆTHER
Tim Adkins is a Director of Digital Life Sciences Operations at ZÆTHER, serving the life science industry by assisting companies reach their desired business outcomes through digital IT/OT solutions. He has 30 years of industry experience as an IT/OT leader in global operational improvements and support, manufacturing system design, and implementation programs.

Barbara Tessier

Technical Project Lead, invoX Pharma

A great opportunity to connect with like-minded professionals in the pharma industry who are passionate about digital tools like QbDVision. Learning about advancements in Digital CMC, tech transfer, and AI in the pharma sector broadened my understanding and inspired me to explore innovative approaches in my work.

Luke Guerrero

COO, QbDVision

A veteran technologist and company leader with a global CV, Luke currently oversees the core business operations across QbDVision and its teams. Before joining QbDVision, he developed, grew, and led key practices for international agency Brand Networks, and spent six years deploying technology and business strategies for PricewaterhouseCoopers’ CIO Advisory consulting unit.

Michael Stapleton

Board Director, QbDVision

Michael Stapleton is a life sciences leader with success spanning leadership roles in software, consumables, instruments, services, consulting, and pharmaceuticals. He is a constant innovator, optimist, influencer, and digital thought leader identifying the next strategic challenge in life sciences, executing and operationalizing on high impact strategic plans to drive growth.

Yash Sabharwal​

President & CEO, QbDVision

Yash Sabharwal is an accomplished inventor, entrepreneur, and executive specializing in the funding and growth of early-stage technology companies focused on life science applications. He has started 3 companies and successfully exited his last two, bringing a wealth of strategic and tactical experience to the team.

Laurent Lefebvre - Headshot

Laurent Lefebvre

RA CMC Director, Novartis

Laurent is the Director of RA GDD CMC at Novartis. With over 10 years of experience working as a worldwide Regulatory CMC Project Lead on blockbuster brands, he is an expert in the entire CMC product lifecycle in global regulatory environments. Laurent has been a core team member of the Novartis Regulatory Strategy and Intelligence for IDMP since 2014 and a member of the EFPIA ICH M4Q support team. He is involved in regular collaborations cross-industry (IDMP roundtables, Pistoia Alliance), digital initiatives (RIM structured authoring, master data & PLM), reviewer of the ISO IDMP guidelines and a Novartis contributor to regulatory intelligence discussions.
Laurent Lefebvre - Headshot

James Maxwell

Life Sciences Innovation Lead, Accenture

James Maxwell is an Innovation Lead at Accentures Global Centre for R&D and Innovation. He leads strategic innovation programs with global Life Sciences organizations to solve challenges, rapidly prototype and prove value for future solutions across the end-to-end Life Sciences value chain. With a background in design, research and innovation strategy he has worked with multiple organizations to take an innovation approach for solving challenges across CMC.
Paul Denny-Gouldson - Headshot

Paul Denny-Gouldson

CSO, Zifo

Paul is the CSO at Zifo RnD Solutions, a global specialist scientific and process informatics service provider working across research, development, manufacturing and clinical domains. He obtained his Ph.D. in Computational Biology from Essex University in 1996 and started his career as a Post Doc, and subsequently Senior Scientist at Sanofi-Synthelabo Toulouse (now Sanofi) for five years, where he managed a multidisciplinary molecular and cell biology department. He has also founded a number of companies focused on combining science, technology and business, and authored more than 25 scientific papers and book chapters.
Chris McCurdy

Chris McCurdy

Chief Architect of Healthcare and Life Sciences at Amazon Web Services

Chris McCurdy serves as Chief Architect of Healthcare and Life Sciences (HCLS) for Amazon Web Services (AWS), where he leads teams responsible for architecting cutting-edge services, unlocking data assets, and opening novel analytics capabilities for customers. With over 20 years of industry experience, Chris plays a key role in envisioning and developing innovative solutions and services that accelerate customer value while improving patient outcomes.
Isabell Hagemann Headshot - Digital CMC Basecamp - QbDVision

Isabell Hagemann

Scientific Assistant, Biological Development, Downstream, Bayer AG

Isabell Hagemann is a biochemical engineer by training and has worked at Bayer AG in the biological development downstream department in 2017. In that time, she has worked on process development, process characterization, and the technology transfers of several biologics using high-throughput development systems, modeling approaches, and knowledge management tools.

Ganga Kalidindi

Global Head TRD Data Assets & Insights, Novartis

As the Global Head TRD Data Assets and Insights at Novartis, Ganga Kalidindi brings a unique combination of Information Technology and Product Development expertise to delivering in a regulatory landscape. Throughout his career, he has striven to make direct positive impact on business providing leadership that creates cross-functional high-performing teams. Focusing on complex business and technical challenges, leading through change, and creating success that takes programs and companies to a winning status.
Fran Leira Headshot - Digital CMC Basecamp - QbDVision

Fran Leira

Global Head of Process Engineering CoE, CSL Behring

Fran Leira is a biopharma Professional with over 20 years of experience in QC, MSAT/Tech Ops at companies like Genentech, GSK, Merck, and Lonza where he supported Product and Process Lifecycle Management at site-based and global roles. He is currently the Global Head of Process Engineering CoE at CSL Behring.

Florian Aupert Headshot - Digital CMC Basecamp - QbDVision

Florian Aupert

Lab Head, Biological Development, Bayer AG

Florian has a B. Sc. and M. Sc. in pharmaceutical biotechnology with a focus on bioprocess engineering. Since 2018, he’s worked at Bayer AG in Biological Development, concentrating on portfolio program management and tech transfer.

Devendra Deshmukh

Global Head, Digital Science Business Operations, Thermo Fisher Scientific

Devendra Deshmukh currently leads Global Business Operations for Digital Science Solutions at Thermo Fisher Scientific. In this role he oversees operations broadly for the business across its product portfolio and leads the global professional services, technical support, and product education teams.

Mark Fish

Managing Director, Scientific Informatics, Accenture

Mark Fish is Managing Director and Global Lead for Accenture’s Scientific Informatics Services Business. Mark has over 25 years of experience in leadership roles in Accenture, Brooks Life Sciences and Thermo Fisher Scientific delivering innovative solutions to the pharmaceutical sector and is passionate about drug discovery and development, translation research and manufacturing transformation. Mark has extensive experience in agile software development, data strategy, process engineering and robotic automation for research, analytical development and quality control in Life Sciences.

Chris Puzzo

Solution Architect, Digital & Data, Zaether

Chris is a Solution Architect with Zaether, focusing on delivering next-generation digital and data solutions for GxP Life Sciences customers. Chris has previously held technical operations roles within multiple gene therapy manufacturers, including Thermo Fisher Scientific’s CDMO organization where he supported various capital projects including the design, build, and startup of new GxP manufacturing capacity.

Victor Goetz, Ph.D

Executive Director, TS/MS New Modalities and Data Strategy, Eli Lilly and Company

Victor Goetz, Ph.D. is the Executive Director of Technical Services New Modalities and Data Strategy at Eli Lilly and Company. He has over 35 years of industry experience in developing and commercializing nine novel medicines to enhance the exchange of knowledge needed to speed the delivery of new medicines to patients. Dr. Goetz holds a BS in chemical engineering from Stanford University and a PhD in chemical and biochemical engineering from the University of Pennsylvania.

Rachelle Howard

Director of Manufacturing Systems Automation and Digital Strategy, Vertex Pharmaceuticals

Rachelle is the Director of Manufacturing Systems Automation and Digital Strategy for Vertex’s Small Molecule Manufacturing Center. She oversees the site Automation Engineering function and has co-led Vertex’s global Digital Manufacturing Transformation program since 2019. She leads several initiatives related to data integrity, data management, and employee education. Rachelle is a graduate of Tufts University and the University of Connecticut where she has degrees in Chemical Engineering and a PhD in Process Control.

Vijay Raju

Vice President, CMC Management, Flagship Pioneering

Vijay currently leads CMC activities to deliver on Pioneering Medicines portfolio. The portfolio is built on Flagship Pioneering’s bio-platforms covering multiple modalities (small molecules, biologics, cell & gene therapies). Vijay was previously in technical leadership roles at Novartis.

Greg Troiano

Head of cGMP Strategic Supply & Operations, mRNA Center of Excellence, Sanofi

Greg serves as Head of cGMP Strategic Supply and Operations at the mRNA Center of Excellence at Sanofi, where he is responsible for all aspects of clinical production and raw material supply chain. He joined Sanofi via acquisition of Translate Bio, where he was Chief Manufacturing Officer and responsible for Technical Operations. Over his 20+ year career in the drug delivery field, Greg had various roles leading the pharmaceutical development of complex formulations, including numerous nano- and microparticle based systems. Greg received his MSE and BS in Biomedical Engineering from The Johns Hopkins University and was elected and inducted into the American Institute for Medical and Biological Engineering (AIMBE) College of Fellows in 2020 for recognition of his accomplishments in drug delivery.

Pat Sacco

Senior Vice President Manufacturing, Quality, and Operations, SalioGen

Pat is a Biotechnology technical operations executive with 30+ years of experience leading and managing technical operations functions at numerous innovative companies in the biotech and life sciences industries. He has a passion for advancing and implementing best practices in pharmaceutical manufacturing.

Diana Bowley

Associate Director, Data & Digital Strategy, AbbVie

Diana is the Associate Director, Data & Digital Strategy in S&T-Biologics Development and Launch leading the organization’s Digital Transformation since October 2021. She joined AbbVie in 2012 in the R&D-Discovery Biologics group focused on antibody and multi-specific protein screening and engineering, leading multiple programs to the cell line development stage. In 2017 she joined Information Research and led a team of IT professionals who supported AbbVie’s Discovery Scientists in Biotherapeutics, Chemistry, Immunology and Neuroscience. She has a PhD in Molecular Biology from The Scripps Research Institute and Bachelor of Science in Chemistry from The University of Northern Iowa.

Robert Dimitri, M.S., M.B.A.

Director Digital Quality Systems, Thermo Fisher Scientific

Robert Dimitri is a Director of Digital Quality Systems in Thermofisher’s Pharma Services Group. Previously he was a Digital Transformation and Innovation Lead in Takeda’s Business Excellence for the Biologics Operating Unit while leading Digital and Data Sciences groups in Manufacturing Sciences at Takeda’s Massachusetts Biologics Site.

Devendra Deshmukh

Global Head, Digital Science Business Operations, Thermo Fisher Scientific

Devendra Deshmukh currently leads Global Business Operations for Digital Science Solutions at Thermo Fisher Scientific. In this role he oversees operations broadly for the business across its product portfolio and leads the global professional services, technical support, and product education teams.

Grant Henderson

Sr. Dir. Manufacturing Science and Technology, VernalBio

Grant Henderson is the Senior Director of Manufacturing Science and Technology at Vernal Biosciences. He has years of expertise in pharmaceutical manufacturing process development/characterization, advanced design of experiments, and principles of operational excellence.

Ryan Nielsen

Life Sciences Global Sales Director, Rockwell Automation

Ryan Nielsen is the Life Sciences Global Sales Director at Rockwell Automation. He has over 17 years of industry experience and a passion for collaboration in solving complex problems and adding value to the life sciences space.

Shameek Ray

Head of Quality Manufacturing Informatics, Zifo

Shameek Ray is the Head of Quality Manufacturing Informatics and Zifo and has extensive experience in implementing laboratory informatics and automation for life sciences, forensics, consumer goods, chemicals, food and beverage, and crop science industries. With his background in services, consulting, and product management, he has helped numerous labs embark on their digital transformation journey.

Max Peterson​

Lab Data Automation Practice Manager, Zifo

Max Petersen is the Lab Data Automation Practice Manager at Zifo responsible for developing strategy for their Lab Data Automation Solution (LDAS) offerings. He has over 20 years of experience in informatics and simulation technologies in life sciences, chemicals, and materials applications.

Michael Stapleton

Board Director, QbDVision

Michael Stapleton is a life sciences leader with success spanning leadership roles in software, consumables, instruments, services, consulting, and pharmaceuticals. He is a constant innovator, optimist, influencer, and digital thought leader identifying the next strategic challenge in life sciences, executing and operationalizing on high impact strategic plans to drive growth.

Matthew Schulze

Head of Digital Pioneering Medicines & Regulatory Systems, Flagship Pioneering

Matt Schulze is a Senior Director in the Flagship Digital, IT, and Informatics team, where he leads and manages the digital evolution for Pioneering Medicines. His role is pivotal in ensuring that digital strategies align with the overall goals and objectives of the Flagship Pioneering initiative.

His robust background in digital life sciences includes expertise in applications, informatics, data management, and IT/OT management. He previously spearheaded Digital Biomanufacturing Applications at Resilience, a CDMO start-up backed by Arch, where he established a team responsible for implementing global manufacturing automation systems, Quality Assurance applications, laboratory systems, and data management applications.

Matt holds a B.S. in Biology and Biotechnology from Worcester Polytechnic Institute and an M.B.A. from the Boston University Questrom School of Business, where he focused on Strategy and Innovation.

Daniel R. Matlis

Founder and President, Axendia

Daniel R. Matlis is the Founder and President of Axendia, an analyst firm providing trusted advice to life science executives on business, technology, and regulatory issues. He has three decades of industry experience spanning all life science and is an active contributor to FDA’s Case for Quality Initiative. Dan is also a member of the FDA’s advisory council on modeling, simulation, and in-silico clinical trials and co-chaired the Product Quality Outcomes Analytics initiative with agency officials.

Kir Henrici

CEO, The Henrici Group

Kir is a life science consultant working domestically and internationally for over 12 years in support of quality and compliance for pharma and biotech. Her deep belief in adopting digital technology and data analytics as the foundation for business excellence and life science innovation has made her a key member of PDA and ISPE – she currently serves on the PDA Regulatory Affairs/Quality Advisory Board

Oliver Hesse

VP & Head of Biotech Data Science & Digitalization, Bayer Pharmaceuticals

Oliver Hesse is the current VP & Head of Biotech Data Science & Digitalization for Bayer, based in Berkeley, California. He has a degree in Biotechnology from TU Berlin and started his career in a Biotech start-up in Germany before joining Bayer in 2008 to work on automation, digitalization, and the application of data science in the biopharmaceutical industry.

John Maguire

Director of Manufacturing Sciences, Sanofi mRNA Center of Excellence

With over 18 years of process engineering experience, John is an expert in the application of process engineering and operational technology in support of the production of life science therapeutics. His work includes plant capability analysis, functional specification development, and the start-up of drug substance manufacturing facilities in Ireland and the United States.

Chris Kopinski

Business Development Executive, Life Sciences and Healthcare at AWS

As a Business Development Executive at Amazon Web Services, Chris leads teams focused on tackling customer problems through digital transformation. This experience includes leading business process intelligence and data science programs within the global technology organizations and improving outcomes through data-driven development practices.

Tim Adkins

Digital Life Science Operations, ZÆTHER

Tim Adkins is a Director of Digital Life Sciences Operations at ZÆTHER, serving the life science industry by assisting companies reach their desired business outcomes through digital IT/OT solutions. He has 30 years of industry experience as an IT/OT leader in global operational improvements and support, manufacturing system design, and implementation programs.

Blake Hotz

Manufacturing Sciences Data Manager, Sanofi

At Sanofi’s mRNA Center of Excellence, Blake Hotz focuses on developing data ingestion and cleaning workflows using digital tools. He has over 5 years of experience in biotech and holds degrees in Chemical Engineering (B.S.) and Biomedical Engineering (M.S.) from Tufts University.

Anthony DeBiase

Offering Manager, Rockwell Automation

Anthony has over 14 years of experience in the life science industry focusing on process development, operational technology (OT) implementation, technology transfer, CMC and cGMP manufacturing in biologics, cell therapies, and regenerative medicine.

Andy Zheng

Data Solution Architect, ZÆTHER

Andy Zheng is a Data Solution Architect at ZÆTHER who strives to grow and develop cutting-edge solutions in industrial automation and life science. His years of experience within the software automation field focused on bringing innovative solutions to customers which improve process efficiency.

Sue Plant

Phorum Director, Regulatory CMC, Biophorum

Sue Plant is the Phorum Director of Regulatory CMC at BioPhorum, a leading network of biopharmaceutical organizations that aims to connect, collaborate, and accelerate innovation. With over 20 years of experience in life sciences, regulatory, and technology, she focuses on improving access to medicines through innovation in the regulatory ecosystem.

Yash Sabharwal​

President & CEO, QbDVision

Yash Sabharwal is an accomplished inventor, entrepreneur, and executive specializing in the funding and growth of early-stage technology companies focused on life science applications. He has started 3 companies and successfully exited his last two, bringing a wealth of strategic and tactical experience to the team.

Joschka Buyel

Director of Product Management, QbDVision

Joschka Buyel is the Director of Product Management at QbDVision. He was previously responsible for the rollout and integration of QbDVision at Bayer and worked on various late-stage projects as a Quality-by-Design Expert for Product & Process Characterization, Process Validation, and Transfers. Joschka has a Ph.D. in Drug Sciences from Bonn University and a M.S. and B.S. in Molecular and Applied Biotechnology from the RWTH University.

Luke Guerrero

COO, QbDVision

A veteran technologist and company leader with a global CV, Luke currently oversees the core business operations across QbDVision and its teams. Before joining QbDVision, he developed, grew, and led key practices for international agency Brand Networks, and spent six years deploying technology and business strategies for PricewaterhouseCoopers’ CIO Advisory consulting unit.

Gloria Gadea Lopez

<